source
- Highlight Therapeutics reports positive Phase 2b results for BO-112 in high‑risk head and neck basal cell carcinomaHighlight Therapeutics announced that its Phase 2b study of BO-112 met the primary endpoint of visual and pathological response at week 24 in patients with localized high‑risk head and neck basal c…
- uniQure shares tumble 41% after Huntington’s gene therapy misses primary endpointuniQure reported updated 48‑month data from its phase 1/2 trial of AMT‑130 in Huntington’s disease. The therapy showed a 44% slowing of disease progression on the composite Unified Huntington’s Dis…Fierce Biotech · 22d agoNegative readoutNegative